Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group

Affiliations

• ¹ Department of Pediatric Oncology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑ku, Tokyo, 104‑0045, Japan. tkumamot@ncc.go.jp.
• ² Department of Hematology and Oncology, Children's Cancer Center, Kanagawa Children's Medical Center, Yokohama, Japan.
• ³ Department of Pediatric Oncology, National Cancer Center Hospital, 5‑1‑1 Tsukiji, Chuo‑ku, Tokyo, 104‑0045, Japan.
• ⁴ Department of Pediatrics, Aich Medical University Hospital, Nagoya, Japan.
• ⁵ Division of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
• ⁶ Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
• ⁷ Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
• ⁸ Department of Pediatrics, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
• ⁹ Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.